loader from loading.io

Episode 410: The Evidence for the Environment’s Impact on Cancer Outcomes

The ONS Podcast

Release Date: 04/10/2026

Episode 427: Pharmacology 101: Resistance Pathways show art Episode 427: Pharmacology 101: Resistance Pathways

The ONS Podcast

“A good way of thinking about this is this is the survival of the fittest clone. There could be a portion of a cancer that naturally has some resistance or ability to survive a particular drug. And over time, as the other cells around it are dying off, that particular clone is able to replicate and continue to survive in the face of that drug therapy and eventually take over as being the fittest clone. At that point, we’re often seeing disease progression,” Danielle Roman, PharmD, BCOP, manager of clinical pharmacy services at the Allegheny Health Network Cancer Institute in Pittsburgh,...

info_outline
Episode 426: Tools to Support Patients and Nurses Through Medical Trauma in Oncology show art Episode 426: Tools to Support Patients and Nurses Through Medical Trauma in Oncology

The ONS Podcast

“When people with PTSD [post-traumatic stress disorder] get quite avoidant—and that can be expressed in so many different ways—the implications can be really profound. I think an important invitation to oncologists and oncology nurses and primary care providers who care for people battling cancer is let’s explore what's underneath these avoidant behaviors. Is it a very practical thing? Or is it that underneath this avoidant behavior is really profound fear?” James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Lenise Taylor, MN,...

info_outline
Episode 425:  How AI Can Help Healthcare Organizations Improve the Cancer Experience show art Episode 425: How AI Can Help Healthcare Organizations Improve the Cancer Experience

The ONS Podcast

“In oncology specifically, where care is complex, artificial intelligence (AI) can really synthesize large volumes of clinical information, flag risks such as treatment complications, and support adherence to evidence-based pathways. For nurses specifically, this enables them more time for direct patient care, clinical judgment, and care coordination, and really practice to the top of their license while reducing repetitive time and administrative tasks,” Jenn Frith, DNP, RN, OCN®, NE-BC, associate vice president of clinical operations at Duke Cancer Institute in Durham, NC, told Jaime...

info_outline
Episode 424: Radiation Site-Specific Side Effects: Cancers of the Pelvis show art Episode 424: Radiation Site-Specific Side Effects: Cancers of the Pelvis

The ONS Podcast

“Think about what organs lie in the radiation field, and anything that lies in that radiation field is likely going to have some potential temporary—hopefully temporary—side effects. If you think about the pelvis, the things that live in there are the bladder, urethra, some bowel, rectum, reproductive organs, skin, some lymph nodes. And so, all of those things could potentially have associated side effects,” ONS member Kayla Kafka-Peterson, BSN, RN, ROCN™, nurse navigator and leader in the brachytherapy and peri-anesthesia programs at UCLA Health, in Los Angeles, CA, told Lenise...

info_outline
Episode 423: Pharmacology 101: Interaction Pathways show art Episode 423: Pharmacology 101: Interaction Pathways

The ONS Podcast

“When we think of drug interactions, specifically, the National Cancer Institute actually defines this as a change in the way a drug acts in the body when taken with certain other drugs, herbals, or foods or when taken with certain medical conditions. Drug interactions may cause the drug to either be more or less effective or cause effects on the body that are not expected,” Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology...

info_outline
Episode 422: An Overview of Chronic Lymphocytic Leukemia for Oncology Nurses show art Episode 422: An Overview of Chronic Lymphocytic Leukemia for Oncology Nurses

The ONS Podcast

“What I appreciate about our patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia is the consideration that they receive a cancer diagnosis, and the best thing for them to do is actually nothing. There is a large population of patients that we don’t recommend any type of treatment. We recommend that they establish care with an oncologist and that they have a relationship with those care teams,” ONS member Caitilin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner at Dana-Farber Cancer Institute in Boston, MA, told Lenise Taylor, MN, RN, AOCNS®,...

info_outline
Episode 421: Medical Trauma in Oncology show art Episode 421: Medical Trauma in Oncology

The ONS Podcast

“There are a huge array of medical dynamics that people endure, and when they leave a lasting impact, a word that we don’t use widely enough is the word ‘trauma.’ There’s an entire category of phenomena in the medical arena that are, in fact, traumatic. One way we know that these experiences are traumatic is that we know that huge portions of people who experience things like cancer do indeed develop problems like [post-traumatic stress disorder],” James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Jaime Weimer, MSN, RN,...

info_outline
Episode 420: Long-Term Myelodysplastic Syndrome Considerations for Oncology Nurses show art Episode 420: Long-Term Myelodysplastic Syndrome Considerations for Oncology Nurses

The ONS Podcast

“We typically think of the disease progressing for our higher-risk patients because many of them already start with increased blasts or a lot of dysplasia. And they have these chromosomal variants that make them prone to evolving into acute myeloid leukemia (AML). With them, we can anticipate that they are going to progress to AML. And that’s what we’re trying to prevent. It’s kind of like a biologic evolution and not a switch,” ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise...

info_outline
Episode 419: Pharmacology 101: Immunomodulators show art Episode 419: Pharmacology 101: Immunomodulators

The ONS Podcast

“Until immunomodulators, patients [with myeloma] did not have a great overall survival rate. But when we introduced lenalidomide, we started seeing our patients have life expectancies between five and seven years—which was unheard of prior to these immunomodulators going forward. I think it’s promising and allows patients to have quality of life versus therapy of life,” ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist...

info_outline
Episode 418: Radiation Site-Specific Side Effects: Colorectal Cancer show art Episode 418: Radiation Site-Specific Side Effects: Colorectal Cancer

The ONS Podcast

“Radiation therapy is often extremely well tolerated in colorectal cancer. Technology has really changed things. But location of the tumor can affect side effects, such as radiation dermatitis. If a patient has a low-lying tumor, if it’s less than six centimeters from the anal verge, the patient is likely to have some skin reaction. It’s good to be proactive if that’s the case,” ONS member Lorraine Drapek, DNP, FNP-BC, AOCNP®, nurse practitioner in the Department of Radiation Oncology at Massachusetts General Hospital in Boston, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®,...

info_outline
 
More Episodes

“Cancer and environmental disasters in particular, but the worsening of our environment, are really things that are great equalizers. And we recognize that we’re all kind of in this world together. We can really face these issues on a more human level. I think always recognizing that if we look at something, we think, ‘Well, that doesn’t relate to me or that problem is it really isn’t my problem’—it sure is,” ONS member Margaret “Peggy” Rosenzweig, PhD, CRNP-C, AOCNP®, FAAN, ONS scholar-in-residence and distinguished service professor of nursing and Nancy Glunt Hoffman Chair in Oncology Nursing at the University of Pittsburgh School of Nursing in Pennsylvania told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the effects of the environment on cancer care and outcomes.

Music Credit: “Fireflies and Stardust” by Kevin MacLeod

Licensed under Creative Commons by Attribution 3.0 

Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 10, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Learning outcome: Nurses caring for people with cancer require knowledge to recognize and address how environmental factors influence cancer care delivery, patient outcomes, and workforce resilience.

Episode Notes 

To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.

To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

Highlights From This Episode

“The process of establishing these research priorities usually happens every three or so years. And there’s a lot of preliminary work of talking to multiple parties of interest regarding what they believe the research priorities are, what nurses are seeing in clinics and in the community, and really multiple opinions regarding where the direction of research for ONS should go. And we heard this time—loud and clear—from researchers, from nurses in clinics and in communities, from scholars, and multiple other interested parties, that the environment in a very broad context was very much a concern and specifically a concern for impact on cancer care delivery, quality, and outcomes.” TS 1:49

“You can take some cancer outcome data and you can take patient data related to home address or zip code or even larger geographic areas and kind of do correlational studies to see ‘Does one impact the other?’ … There’s been a lot of those in the literature. But they are very helpful because they’re starting to define this idea that beyond the idea of just demographics—gender, age, race—that the whole concept of neighborhood and the influences of the neighborhood do impact cancer outcomes. And that’s where we’re seeing the sort of explosion in literature across multiple malignancies, stages of cancer, and across multiple questions—specific kinds of outcomes, everything from quality of life to tumor progression.” TS 8:43

“There is growing literature around how cancer delivery can be better prepared for climate-related disasters. … There’s a good article by Pamela Ginex that was published in Supportive Care in Cancer talking about climate disasters and oncology care. And that was really a systematic review looking at published literature and starting to classify where are the disruptions and how could we think about that from a research perspective. They ended up saying there are these patient-level outcome disruptions that of course include treatment disruption but also include this inability to communicate with the oncology care team, which is quite distressing. And there’s a workforce disruption because there are very distressed clinicians who are experiencing the same climate-related disaster in their own lives and feeling like they are torn between their commitment to work and their commitment to family.” TS 13:25

“After all these years in oncology nursing, I am convinced that we have to get the consideration of neighborhood. I think we do have to get back to the neighborhood level in order to boost the resilience of communities against cancer throughout the cancer trajectory.” TS 31:53

“Let’s take some of this to the community and boost the community in that way. I really feel like we have to think about just boots on the ground outside of the cancer center, instead of just documenting disparities or even doing interventional work, but still within our little ivory towers.” TS 34:21

“You see the work of many in looking at the specific environmental risks to nurses through the toxic chemicals to which were exposed. But then thinking about the people who aren’t as protected as nurses and the environmental workers, who are usually contracted out or not in unions, who don’t have some of the same protections that nurses or other healthcare workers might have, and they are exposed to the chemicals without proper training or sometimes without protection. All of these things are very much worthy of an oncology nursing voice elevating these questions and saying, ‘How can we study this? How can we best mitigate some of these risks?’ Oncology nursing—we have to use our respect and good name in elevating all of these questions.” TS 35:39